Yantai Dongcheng Biochemicals (002675.SZ): A new dual-target radiopharmaceutical for in vivo diagnosis has received clinical trial approval.

20/09/2024

GMT Eight

Yantai Dongcheng Biochemicals (002675.SZ) announced that its controlling subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. (referred to as "LNC") has received the drug clinical trial approval notification for 18F-LNC1007 injection from the China National Medical Products Administration and will conduct clinical trials in the near future. The company's research product, 18F-LNC1007 injection, is a novel dual-targeted radioactive diagnostic drug that targets fibroblast activation protein (FAP) and integrin v3 at the same time. It is intended for the diagnosis of adult solid tumors that are positive for FAP and v3.

Guangdong Rongtai Industry (600589.SH): The company still has restricted intangible assets, investment properties, and the book value of construction in progress totaling approximately 179 million yuan.

ZERO2IPO (01945) spent HKD 23,000 to repurchase 22,800 shares on September 20th.

Contact: contact@gmteight.com

Yantai Dongcheng Biochemicals (002675.SZ): A new dual-target radiopharmaceutical for in vivo diagnosis has received clinical trial approval.

RECOMMEND

HK Stock Market Move | MANULIFE-S(00945) rose by over 3%, the third quarter's new manufacturing business value increased by 40.5% year-on-year, hitting a new high.

HK Stock Market Move | LI NING (02331) rises over 5% again, introducing Red Dragon China to establish a joint venture company to develop the brand's overseas market business.

Guosen: Maintains a rating of "Outperform" for CHINAHONGQIAO (01378) as Shandong Hongqiao's profits have increased quarter-on-quarter and year-on-year in the third quarter.